AVCN.F Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.28 |
| 52 Week High | CA$0.53 |
| 52 Week Low | CA$0.17 |
| Beta | 1.32 |
| 11 Month Change | 21.35% |
| 3 Month Change | 23.93% |
| 1 Year Change | -22.67% |
| 33 Year Change | -60.65% |
| 5 Year Change | -82.28% |
| Change since IPO | -89.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVCN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.6% | -0.1% | 1.9% |
| 1Y | -22.7% | 22.3% | 32.8% |
Return vs Industry: AVCN.F underperformed the US Pharmaceuticals industry which returned 21.8% over the past year.
Return vs Market: AVCN.F underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| AVCN.F volatility | |
|---|---|
| AVCN.F Average Weekly Movement | 24.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVCN.F's share price has been volatile over the past 3 months.
Volatility Over Time: AVCN.F's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Avicanna Inc. Fundamentals Summary
| AVCN.F fundamental statistics | |
|---|---|
| Market cap | US$33.68m |
| Earnings (TTM) | -US$5.54m |
| Revenue (TTM) | US$18.51m |
1.9x
P/S Ratio-6.3x
P/E RatioIs AVCN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCN.F income statement (TTM) | |
|---|---|
| Revenue | CA$24.87m |
| Cost of Revenue | CA$14.41m |
| Gross Profit | CA$10.46m |
| Other Expenses | CA$17.90m |
| Earnings | -CA$7.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.064 |
| Gross Margin | 42.05% |
| Net Profit Margin | -29.90% |
| Debt/Equity Ratio | 17.4% |
How did AVCN.F perform over the long term?
See historical performance and comparison